Doctors at the Ella Institute, headed by Prof. Jacob Schachter, published encouraging clinical results in treating metastatic melanoma patients.
The article was published in May in Clinical Cancer Research Journal.
Regression of tumor burden and significant prolongation of survival was achieved in 50% of patients treated by the TIL immunotherapy technology at the Ella Institute.
Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.
Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O,
Hershkovitz L, Levy D, Kubi A, Hovav E, Chermoshniuk N,
Shalmon B, Hardan I, Catane R, Markel G, Apter S, Ben-Nun A,
Kuchuk I, Shimoni A, Nagler A, Schachter J.
Clin Cancer Res. 2010 16(9):2646-55.
http://www.ncbi.nlm.nih.gov/pubmed/20406835 |
